Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis.
Marina Barcena-VarelaHannah PaishLaura AlvarezIker UriarteMaria U LatasaEva SantamariaMiriam RecaldeMaria GarateAlex ClaveriaLeticia ColynMaría ArechederraMaria J IraburuMalgorzata MilkiewiczPiotr MilkiewiczBruno SangroStuart M RobinsonJeremy FrenchAna Pardo-SagantaJulen OyarzabalFelipe ProsperKrista RomboutsFiona OakleyJelena MannCarmen BerasainMatias A AvilaMaite G Fernandez-BarrenaPublished in: Gut (2020)
Dual G9a/DNMT1 inhibition by compounds like CM272 may be a novel therapeutic strategy for treating liver fibrosis.